A Phase 2 trial of gemcabene in patients with Non-alcoholic-fatty-liver-disease and Non-alcoholic-steatohepatitis (NAFLD/NASH)
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2017
At a glance
- Drugs Gemcabene (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms AZURE-1
- 25 Sep 2017 According to a Gemphire Therapeutics media release, plans to initiate this trial in the fourth quarter of 2017.
- 14 Aug 2017 According to a Gemphire Therapeutics media release, top-line results for this study expected in second half of 2018.
- 16 Mar 2017 New trial record